TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11136688

Group type: EXPERIMENTAL
Intervention: Aldosterone levels in anterior interventricular vein (AIV)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aldosterone levels in coronary sinus (CS)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ACE activity levels in AIV
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: BNP levels in AIV
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Correlation of aldosterone levels with LVEDP
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Correlation of aldosterone levels with LV ejection fraction
Number of subjects: 68
Study: 9184370

Group type: EXPERIMENTAL
Intervention: Overnight accelerated bacteriological evaluation (ABLE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empirical prescribing of antibiotics
Number of subjects: 0
Study: 7882816

Group type: COMPARATOR
Intervention: Potato only for the first meal, Potato with fat for the second meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Potato with fat for the first meal, Potato for the second meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Potato only for the first meal, Potato only for the second meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Potato with fat for the first meal, Potato with fat for the second meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Potato with fat for the first meal, Potato without fat for the second meal
Number of subjects: 9
Study: 3283783

Group type: EXPERIMENTAL
Intervention: Amitriptyline (median dose 125 mg daily)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 141
Study: 30217552

Group type: EXPERIMENTAL
Intervention: High-dose baclofen (30-270 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High-dose baclofen
Number of subjects: 23
Study: 28025372

Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 608
Study: 26499426

Group type: EXPERIMENTAL
Intervention: Malnutrition (underweight)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Malnutrition (stunting)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Malnutrition (wasting)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low weight for age
Number of subjects: 76
Study: 23324599

Group type: EXPERIMENTAL
Intervention: Vitamin D (VD) 1,000 IU daily for four months
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 21075373

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160mg daily for 8 weeks
Number of subjects: 53
Study: 17554242

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 28
Study: 16627414

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) only pacing
Number of subjects: 172

Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 172
Study: 14603195

Group type: EXPERIMENTAL
Intervention: Miniaturized sequential device (CECT group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard calf-length sequential IPC device (SCD group)
Number of subjects: 100
Study: 15255249

Group type: EXPERIMENTAL
Intervention: Unilateral DBS of the STN
Number of subjects: 12
Study: 17216957

Group type: EXPERIMENTAL
Intervention: Egyptian version of Children's Health Locus of Control scale (40 statements, Yes/No format and 4-point Likert scale format)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Children's Health Locus of Control scale
Number of subjects: 930
Study: 7557512

Group type: EXPERIMENTAL
Intervention: Dapiprazole 0.5% and Pilocarpine 2%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dapiprazole 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pilocarpine 2%
Number of subjects: 60
Study: 2181858

Group type: EXPERIMENTAL
Intervention: Canola-oil-based diet (CAN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunflower-oil-based diet (SUN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-experimental mixed-fat diet (Pre-exp)
Number of subjects: 0
Study: 463054

Group type: EXPERIMENTAL
Intervention: Pop music during exercise on a bicycle ergometer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pop music
Number of subjects: 0
Study: 31971410

Group type: EXPERIMENTAL
Intervention: BWL + BIAS
Number of subjects: 72

Group type: COMPARATOR
Intervention: BWL
Number of subjects: 72
Study: 30694100

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (Winclove 607 based on Omnibiotic® 10 AAD) for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 26856344

Group type: EXPERIMENTAL
Intervention: Acute intermittent hypoxia (AIH) following ibuprofen pretreatment (800 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Acute intermittent hypoxia (AIH) following placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ibuprofen pretreatment (800 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acute intermittent hypoxia (AIH)
Number of subjects: 9
Study: 25901619

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (3-dimensional MRI preoperative planning)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional TKA (non-patient-specific instrumentation)
Number of subjects: 30
Study: 23536584

Group type: EXPERIMENTAL
Intervention: Lixisenatide morning injection
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Lixisenatide evening injection
Number of subjects: 680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study: 21380982

Group type: EXPERIMENTAL
Intervention: Postural education program over 6 weeks (6 sessions)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual school curriculum (Control Group)
Number of subjects: 137
Study: 19272067

Group type: EXPERIMENTAL
Intervention: Intrathoracic impedance monitoring ON
Number of subjects: 532

Group type: COMPARATOR
Intervention: Intrathoracic impedance monitoring OFF
Number of subjects: 532
Study: 17240493

Group type: EXPERIMENTAL
Intervention: DTaP-HepB-IPV vaccine coadministered with PCV and Hib
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Separate administration of DTaP, HepB, IPV, Hib, and PCV
Number of subjects: 1008
Study: 15709331

Group type: EXPERIMENTAL
Intervention: One benchmark (100% MVC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Three benchmarks (25%, 75%, and 100% MVC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 11571993

Group type: EXPERIMENTAL
Intervention: Cognitive, psycho-educational and supportive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 9305417

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 or 1.0 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 8199756

Group type: EXPERIMENTAL
Intervention: Physician A's practices
Number of subjects: 200

Group type: COMPARATOR
Intervention: Physician B's practices
Number of subjects: 200
Study: 31919583

Group type: EXPERIMENTAL
Intervention: Quinoa biscuits (15 g daily for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control biscuits (iso-energetic, wheat flour)
Number of subjects: 40
Study: 30594190

Group type: EXPERIMENTAL
Intervention: Chronic pain self-management course (2.5-h weekly sessions for 6 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low-impact outdoor physical activity (1-h weekly sessions for 6 weeks)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Chronic pain self-management course
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low-impact outdoor physical activity
Number of subjects: 121
Study: 27055527

Group type: COMPARATOR
Intervention: Eslicarbazepine acetate monotherapy (1200 or 1600 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate monotherapy
Number of subjects: 0
Study: 26643917

Group type: EXPERIMENTAL
Intervention: Online theory-based intervention (self-affirmation manipulation, health messages based on the theory of planned behaviour, implementation intention tasks)
Number of subjects: 2621

Group type: EXPERIMENTAL
Intervention: Online theory-based intervention
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2621
Study: 23430004

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training during the program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no VR training)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (VR and control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 27
Study: 20565345

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol 50,000 IU daily for 10 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low-dose cholecalciferol 3000 IU daily for 30 days, followed by 1000 IU daily for 60 days
Number of subjects: 59
Study: 18420876

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 60
Study: 16643492

Group type: EXPERIMENTAL
Intervention: Antireflux serous-lined extramural tunnel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct anastomosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (antireflux and direct)
Number of subjects: 60
Study: 14657545

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (1200 mg/d for 10 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no hydrocortisone treatment)
Number of subjects: 28
Study: 10816186

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 268

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 268
Study: 8780337

Group type: EXPERIMENTAL
Intervention: 2.5 g/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5.1 g EPA + DHA/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7.7 g EPA + DHA/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1452381

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 6.25 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3881175

Group type: EXPERIMENTAL
Intervention: High dose human leukocyte alpha-interferon (10 X 10(6) units/day for 28 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low dose human leukocyte alpha-interferon (1 X 10(6) units/day for 28 days)
Number of subjects: 30
Study: 29894774

Group type: EXPERIMENTAL
Intervention: Video-based m-health system for health education and symptom self-management
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (regular treatments only)
Number of subjects: 60
Study: 27438995

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride, 120 mg/d
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 25442691

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 4716

Group type: EXPERIMENTAL
Intervention: Male circumcision of male partners
Number of subjects: 4716
Study: 22281244

Group type: EXPERIMENTAL
Intervention: Community-based behavior change management intervention for essential newborn care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20713879

Group type: EXPERIMENTAL
Intervention: IMC‐A12 monotherapy (10 mg/kg IV every 2 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IMC‐A12 plus cetuximab (10 mg/kg IMC-A12 and 500 mg/m2 cetuximab IV every 2 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IMC‐A12 plus cetuximab (arm C, same as arm B)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IMC‐A12 (serious adverse events)
Number of subjects: 64
Study: 18413068

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 150 mg/day (days 3 to 7) + oral phytoestrogen (Cimicifuga racemosa) 120 mg/day (days 1 to 12)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Clomiphene citrate 150 mg/day (days 3 to 7)
Number of subjects: 119
Study: 16190795

Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate (ER-MPH) 40 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate (ER-MPH) 20 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: OROS-methylphenidate (OROS-MPH) 36 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: OROS-methylphenidate (OROS-MPH) 18 mg
Number of subjects: 53
Study: 12481675

Group type: EXPERIMENTAL
Intervention: Activated charcoal (10 g and 20 g) with saline cathartics (Na2SO4 and MgSO4)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Activated charcoal (10 g) with magnesium sulphate and propantheline (15 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Activated charcoal (10 g) with metoclopramide (10 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo liquid
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 5
Study: 9932569

Group type: EXPERIMENTAL
Intervention: 0.4 mg misoprostol administered orally
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.2 mg misoprostol administered vaginally
Number of subjects: 30
Study: 7768257

Group type: EXPERIMENTAL
Intervention: CHF1194 tablet (20 mg piroxicam)
Number of subjects: 12
Study: 2181701

Group type: EXPERIMENTAL
Intervention: Oral iron 2 mg/kg/d until the age of 6 months
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intramuscular iron dextran 100 mg between the ages of 6 and 8 weeks
Number of subjects: 2
Study: 111279

Group type: EXPERIMENTAL
Intervention: LAAM (1-Alpha-acetylmethadol) administered every other day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Methadone administered every day
Number of subjects: 17
Study: 30702405

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional etch-and-rinse
Number of subjects: 34

Group type: COMPARATOR
Intervention: Self-etching systems
Number of subjects: 34
Study: 29905384

Group type: EXPERIMENTAL
Intervention: CLNP/BPO 3%
Number of subjects: 351

Group type: COMPARATOR
Intervention: ADA + CLNP
Number of subjects: 351
Study: 26634889

Group type: EXPERIMENTAL
Intervention: Multimarker model combining blood urea nitrogen (BUN), chloride, interleukin (IL)-6, cTnI, sST-2, and VEGFR-1
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Late biomarker measurements
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Baseline levels of biomarkers
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Multimarker models
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Subsequent measurements of biomarkers
Number of subjects: 2033
Study: 25180869

Group type: EXPERIMENTAL
Intervention: High-dose terlipressin (1 mg/6-8 h, n=27)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low-dose terlipressin (1 mg/12 h, n=29)
Number of subjects: 56
Study: 21982700

Group type: EXPERIMENTAL
Intervention: Remote telemedical management (RTM)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 710
Study: 19862519

Group type: EXPERIMENTAL
Intervention: (18)F-DOPA PET/CT
Number of subjects: 25

Group type: COMPARATOR
Intervention: CT
Number of subjects: 25

Group type: COMPARATOR
Intervention: (18)F-DOPA PET
Number of subjects: 25
Study: 17658663

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% paste
Number of subjects: 40
Study: 16210047

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.1 mg/kg weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12765673

Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Enteral or oral nutrition
Number of subjects: 128
Study: 10695777

Group type: EXPERIMENTAL
Intervention: artemisinin (total dose of 60 mg/kg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: artesunate (total dose of 12 mg/kg over five days)
Number of subjects: 126

Group type: COMPARATOR
Intervention: artemisinin (effectiveness group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: artesunate (effectiveness group)
Number of subjects: 126
Study: 8568294

Group type: EXPERIMENTAL
Intervention: Envelope subunit vaccine products
Number of subjects: 50

Group type: COMPARATOR
Intervention: Serum from HIV-1-infected persons
Number of subjects: 50
Study: 1764826

Group type: EXPERIMENTAL
Intervention: Subjective visual echocardiographic estimate of LVEF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cubed M-mode formula
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Teichholz M-mode formula
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Length-area method from the four-chamber view
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simpson's single plane formula
Number of subjects: 40
Study: 6887360

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole 2 gm initially and 1 gm 4 times daily for 3 days (group 1)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole 2 gm initially and 1 gm 4 times daily for 7 days (group 2)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole 2 gm initially and 1 gm 4 times daily for 14 days (group 3)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole 2 gm initially and 1 gm 4 times daily for 21 days (group 4)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole (3-day course)
Number of subjects: 146
Study: 31294505

Group type: EXPERIMENTAL
Intervention: Success-based orientation
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Simultaneous success-based and failure-based orientation
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Failure-based orientation
Number of subjects: 394
Study: 27436502

Group type: EXPERIMENTAL
Intervention: Ultracongruent (UC) tibial inserts
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cruciate retaining (CR) tibial inserts
Number of subjects: 105
Study: 26383722

Group type: EXPERIMENTAL
Intervention: Visually Guided Laser Balloon (VGLB)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Standard irrigated radiofrequency ablation (RFA)
Number of subjects: 353
Study: 24144440

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (various weight-based doses)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 21335032

Group type: EXPERIMENTAL
Intervention: PCV13 Lot 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13 Lot 2
Number of subjects: 0
Study: 19813462

Group type: EXPERIMENTAL
Intervention: Test formulation (alendronate 70 mg tablets)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Reference formulation (alendronate 70 mg)
Number of subjects: 80
Study: 18164920

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15180739

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Choice of tests (Colonoscopy or CT colonography)
Number of subjects: 1009
Study: 11147625

Group type: EXPERIMENTAL
Intervention: Chest X-ray screening
Number of subjects: 0
Study: 8862262

Group type: COMPARATOR
Intervention: Steroid therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Medial epicondylectomy and external decompression
Number of subjects: 39
Study: 1725151

Group type: EXPERIMENTAL
Intervention: Cefixime 8 mg/kg once daily at bedtime for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amoxicillin 50 mg/kg/day in 3 divided doses for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefixime and Amoxicillin
Number of subjects: 40
Study: 6724511

Group type: COMPARATOR
Intervention: Child-Turcotte criteria (CTC) score
Number of subjects: 245
Study: 31580003

Group type: EXPERIMENTAL
Intervention: Transvaginal (TV) route
Number of subjects: 58

Group type: COMPARATOR
Intervention: Transabdominal (TA) route
Number of subjects: 58
Study: 30083110

Group type: EXPERIMENTAL
Intervention: Cinemotion training (delivered in weekly group sessions)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cinemotion training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 31
Study: 29282952

Group type: EXPERIMENTAL
Intervention: Needle knife therapy combined with rotation traction manipulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rotation traction manipulation (Control)
Number of subjects: 80
Study: 22432484

Group type: EXPERIMENTAL
Intervention: LI4 acupressure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Touch without massage (Control)
Number of subjects: 100
Study: 20473733

Group type: EXPERIMENTAL
Intervention: Chinese medicine comprehensive therapy (Oleum fructus bruceas, Ganji Decoction, Ailitong)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Chinese medicine comprehensive therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Chemotherapeutic agents with iodized oil chemo-embolization and analgesics
Number of subjects: 97
Study: 18355648

Group type: EXPERIMENTAL
Intervention: Upright stance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 0
Study: 16202258

Group type: EXPERIMENTAL
Intervention: Oral Leflunomide (LEF)
Number of subjects: 51

Group type: COMPARATOR
Intervention: IV Cyclophosphamide
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) in relapsed patients
Number of subjects: 51
Study: 12211512

Group type: EXPERIMENTAL
Intervention: Higher frequency (5-7 days per week)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Moderate intensity (45%-55% of maximum heart rate reserve)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Higher intensity (65%-75% of maximum heart rate reserve)
Number of subjects: 379